MYGN - MYRIAD GENETICS INC
4.5
0.140 3.111%
Share volume: 1,176,544
Last Updated: 03-31-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$4.36
0.14
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-07-2024 | 11-08-2024 | 02-28-2025 | 05-07-2025 | 08-06-2025 | 11-04-2025 | 02-24-2026 | |
| Cash flow financing | -8.800 M | 2.400 M | -3.100 M | 2.100 M | 13.600 M | 2.600 M | 56.200 M | -8.200 M | |
| Other financing cash flows | -8.800 M | -600.000 K | -3.100 M | -1.300 M | -5.900 M | -100.000 K | -400.000 K | -8.400 M | |
| Cash flow | -34.500 M | -1.400 M | 5.100 M | 2.800 M | -11.000 M | -17.900 M | 71.100 M | -3.600 M | |
| Net income | -26.000 M | -36.700 M | -22.100 M | -42.500 M | -100.000 K | -330.500 M | -27.400 M | -7.900 M | |
| Depreciation | 15.700 M | 15.100 M | 15.600 M | 14.800 M | 14.400 M | 14.100 M | 12.600 M | 12.600 M | |
| Changes in inventories | 1.800 M | 0.000 | 0.000 | 0.000 | 900.000 K | 0.000 | 0.000 | 0.000 | |
| Changes in receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Investing Cashflow | -7.100 M | -6.400 M | 7.500 M | -5.900 M | -8.300 M | -6.900 M | -6.200 M | -6.000 M | |
| Net Borrowings | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Investing Activity Other | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividends Paid | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Exchange Rate Effect | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditures | 8.600 M | 8.900 M | 6.300 M | 5.900 M | 5.300 M | 2.800 M | 2.800 M | 4.700 M | |
| Cash Change | -35.300 M | -4.400 M | 8.600 M | 2.100 M | -10.900 M | -17.300 M | 71.100 M | -4.300 M |